These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 24850606)

  • 21. Antiatherosclerotic effects of long-term maximally intensive statin therapy after acute coronary syndrome: insights from Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin.
    Puri R; Nissen SE; Shao M; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; Uno K; Kataoka Y; Nicholls SJ
    Arterioscler Thromb Vasc Biol; 2014 Nov; 34(11):2465-72. PubMed ID: 25212234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
    Wlodarczyk J; Sullivan D; Smith M
    Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.
    Folse H; Sternhufvud C; Andy Schuetz C; Rengarajan B; Gandhi S
    Clin Ther; 2014 Jan; 36(1):58-69. PubMed ID: 24417785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is rosuvastatin really a more efficient therapeutic option than atorvastatin?
    Soto J; Fernandez de Bobadilla J
    Value Health; 2006; 9(4):276-7; author reply 277-9. PubMed ID: 16903999
    [No Abstract]   [Full Text] [Related]  

  • 25. Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
    Tungsubutra W; Phongtuntakul B
    J Med Assoc Thai; 2015 Feb; 98(2):129-36. PubMed ID: 25842792
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NLRP3 inflammasome activation in coronary artery disease: results from prospective and randomized study of treatment with atorvastatin or rosuvastatin.
    Satoh M; Tabuchi T; Itoh T; Nakamura M
    Clin Sci (Lond); 2014 Feb; 126(3):233-41. PubMed ID: 23944632
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
    Stender S; Schuster H; Barter P; Watkins C; Kallend D;
    Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial.
    de Zeeuw D; Anzalone DA; Cain VA; Cressman MD; Heerspink HJ; Molitoris BA; Monyak JT; Parving HH; Remuzzi G; Sowers JR; Vidt DG
    Lancet Diabetes Endocrinol; 2015 Mar; 3(3):181-90. PubMed ID: 25660356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
    Schuetz CA; van Herick A; Alperin P; Peskin B; Hsia J; Gandhi S
    J Med Econ; 2012; 15(6):1118-29. PubMed ID: 22712873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [CORRECTION OF BILE FLOW CHARACTERISTICS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE IN COMBINATION WITH HYPERURICEMIA].
    Barabanchyk OV; Svintsits'kyĭ AS; Kozak NP
    Lik Sprava; 2014 Nov; (11):48-53. PubMed ID: 25528832
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.
    Stalenhoef AF; Ballantyne CM; Sarti C; Murin J; Tonstad S; Rose H; Wilpshaar W
    Eur Heart J; 2005 Dec; 26(24):2664-72. PubMed ID: 16143705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction.
    Deguchi I; Horiuchi Y; Hayashi T; Sehara Y; Kato Y; Ohe Y; Fukuoka T; Maruyama H; Sano H; Nagamine Y; Tanahashi N
    J Stroke Cerebrovasc Dis; 2014 Sep; 23(8):2007-2011. PubMed ID: 25066602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of effects of atorvastatin (20 mg) versus rosuvastatin (10 mg) therapy on mild coronary atherosclerotic plaques (from the ARTMAP trial).
    Lee CW; Kang SJ; Ahn JM; Song HG; Lee JY; Kim WJ; Park DW; Lee SW; Kim YH; Park SW; Park SJ
    Am J Cardiol; 2012 Jun; 109(12):1700-4. PubMed ID: 22440123
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Switching from high-efficacy lipid-lowering therapies [atorvastatin or rosuvastatin] to simvastatin and the results on low-density lipoprotein cholesterol level.
    J Med Assoc Thai; 2015 Jan; 98(1):21-5. PubMed ID: 25775727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery Belux: comparison of rosuvastatin with atorvastatin in hypercholesterolaemia.
    Herregods MC; Daubresse JC; Michel G; Lamotte M; Vissers E; Vandenhoven G;
    Acta Cardiol; 2008 Aug; 63(4):493-9. PubMed ID: 18795588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of statins on progression of atherosclerosis: rationale and design of SATURN (Study of Coronary Atheroma by InTravascular Ultrasound: effect of Rosuvastatin versus AtorvastatiN).
    Nicholls SJ; Borgman M; Nissen SE; Raichlen JS; Ballantyne C; Barter P; Chapman MJ; Erbel R; Libby P
    Curr Med Res Opin; 2011 Jun; 27(6):1119-29. PubMed ID: 21446892
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.
    Weinstein DL; Williams LA; Carlson DM; Kelly MT; Burns KM; Setze CM; Lele A; Stolzenbach JC
    Clin Ther; 2013 Aug; 35(8):1186-98. PubMed ID: 23891363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes.
    Betteridge DJ; Gibson JM
    Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [On the current debate on lowering LDL cholesterol with ezetimibe].
    Schunn H
    Dtsch Med Wochenschr; 2010 Nov; 135(44):2202; author reply 2202. PubMed ID: 20979010
    [No Abstract]   [Full Text] [Related]  

  • 40. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.